Online ISSN: 2515-8260

Keywords : nervous system

Wonders of Phytomedicine in the management of neurological disorders

Gurria .; Iqbaljit Kaur; Srijana Sharma; Keerti Bhardwaj

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 2899-2914

Neurological disorders exhibit its impact on global health. The term neurological disorders mean any condition that occurs due to dysfunction in nervous system or brain as a result shows plethora of symptoms such as sensation loss, pain, muscle weakness, etc. Utilization of synthetic drugs to treat neurological disorder is quite challenging as it has some drawbacks like not cost effective, unavoidable and serious side effects as well as less patient compliance. Therefore, phytomedicines has been preferred as an alternative treatment of neurological disorders due to its variety of merits like cheap, exert negligible side effects, etc. Herbs can be prescribed as a single entity or mixture of different plants against such disorders. This review describes the phytomedicines used to treat CNS specific pharmacologic effects (like anxiolytic, anti-convulsant, analgesic, etc.), ranging from entire plant, bark, flowers, roots, fruit, stem and seeds.

Clinical-Neurophysiologic, Immunological Features And Diagnosis Of Antifosfolipid Syndrome By Cerebra-Vascular Disorders At Background Systemic Diseases Of Connective Tissue

Oybek Bustanov; Nargiza Nasirdinova; Oydin Kuchkarova; Odinahon Kuchkarova

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 5768-5775

Antiphospholipid Syndrome (AFS) is one of the current multidisciplinary problems of modern medicine and is being investigated as a unique example of autoimmune thrombotic vasculopathy. This syndrome was first described in the context of Systemic lupus erythematosus (TSA) and was referred to as anticardiolipin syndrome, later renamed antiphospholipid syndrome (AFS) by the same authors. There is an immunological predisposition to increased synthesis of antiphospholipid antibodies (AFL) and most of them have been detected in relatives of patients with AFS.
The prevalence of AFS in the population is still unknown. It is possible that the synthesis of antiphospholipid antibodies (AFL) may be normal, but often low levels of antibodies are observed in the blood of a healthy person. According to various data, the rate of antibody cardiolipin (ACL) in the population varies from 0 to 14%, averaging 2-4%, with high titers detected in about 0.2% of donors.1 In Uzbekistan, systemic connective tissue is found in several people per year. The disease develops antibodies to the interaction with phospholipids - components of the cell membrane.